Pharmacologic Options for the Treatment of Sarcopenia
The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Abstract
Sarcopenia is now clinically defined as a loss of muscle mass coupled with functional deterioration (either walking speed or distance or grip strength). Based on the FRAX studies suggesting that the questions without bone mineral density can be used to screen for osteoporosis, there is now a valid simple questionnaire to screen for sarcopenia, i.e., the SARC-F. Numerous factors have been implicated in the pathophysiology of sarcopenia. These include genetic factors, mitochondrial defects, decreased anabolic hormones (e.g., testosterone, vitamin D, growth hormone and insulin growth hormone-1), inflammatory cytokine excess, insulin resistance, decreased protein intake and activity, poor blood flow to muscle and deficiency of growth derived factor-11. Over the last decade, there has been a remarkable increase in our understanding of the molecular biology of muscle, resulting in a marked increase in potential future targets for the treatment of sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. High-dose testosterone increases muscle power and function, but has a number of potentially limiting side effects. Other drugs in clinical development include selective androgen receptor molecules, ghrelin agonists, myostatin antibodies, activin IIR antagonists, angiotensin converting enzyme inhibitors, beta antagonists, and fast skeletal muscle troponin activators. As sarcopenia is a major predictor of frailty, hip fracture, disability, and mortality in older persons, the development of drugs to treat it is eagerly awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple pathways are involved in the loss of muscle mass arising from aging, malnutrition, obesity, inflammation and inactivity, which offers many targets for therapeutic intervention [102].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [102]
In the citing paper
“Multiple pathways are involved in the loss of muscle mass arising from aging, malnutrition, obesity, inflammation and inactivity, which offers many targets for therapeutic intervention [102].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [102]
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051
Frailty Consensus: A Call to Action
Morley, J. E., Vellas, B., Abellan van Kan, G., Anker, S. D., Bauer, J. M., Bernabei, R., Cesari, M., Chumlea, W. C., Doehner, W., Evans, J., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.03.022 · Cited by 4,043 · cited 1×
“Fatigue is an important component of the frailty phenotype that is separate from sarcopenia [33, 34].”
BackgroundSelf-citationFielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Self-citationBauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553
Self-citationRejuvenation of aged progenitor cells by exposure to a young systemic environment
Conboy, I. M., Conboy, M. J., Wagers, A. J., Girma, E. R., Weissman, I. L., & Rando, T. A. (2005) · Nature · doi:10.1038/nature03260 · Cited by 2,287 · cited 1×
“Studies with parabiotic mice have shown that the combination of a young and an old mouse leads to rejuvenation in the muscle of the older mouse [65].”
BackgroundEffects of Human Growth Hormone in Men over 60 Years Old
Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., & Mattson, D. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230101 · Cited by 1,555
Pahor, M., Guralnik, J. M., Ambrosius, W. T., Blair, S., Bonds, D. E., Church, T. S., Espeland, M. A., Fielding, R. A., Gill, T. M., Groessl, E. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.5616 · Cited by 1,427 · cited 1×
“As was shown by the LIFE study, aerobic exercise can also decrease functional decline in lower limb muscles [74].”
MethodMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
SARC-F: A simple questionnaire to rapidly diagnose sarcopenia
Malmstrom, T. K., & Morley, J. E. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.018 · Cited by 1,319 · cited 1×
“without Bone Mineral Density are highly predictive of fracture risk [14], we developed a simple sarcopenic questionnaire to predict poor muscle function (Table 2) [15].”
BackgroundSelf-citationSARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“This questionnaire has been shown to be a valid predictor of poor outcomes similar to that of the FNIH (walking speed) definition in both the United States and Asia [13, 16–18].”
ResultSelf-citationSarcopenia with limited mobility: an international consensus
Morley, J. E., Abbatecola, A. M., Argiles, J. M., Baracos, V., Bauer, J., Bhasin, S., Cederholm, T., Stewart Coats, A. J., Cummings, S. R., Evans, W. J., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.04.014 · Cited by 1,125
Self-citationMuscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089 · cited 1×
“This activates the phosphoinositide 3-kinase (PI3K)-AKT—mammalian target of rapamycin (mTOR) signaling pathway [56].”
BackgroundSandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
Sarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the Elderly
Baumgartner, R. N., Wayne, S. J., Waters, D. L., Janssen, I., Gallagher, D., & Morley, J. E. (2004) · Obesity Research · doi:10.1038/oby.2004.250 · Cited by 937 · cited 1×
“This suggests that expression of perilipin 2 may play a role in the development of obese sarcopenia [42, 43].”
BackgroundSelf-citationTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922 · cited 1×
“increased muscle strength in older persons [92–94], numerous studies have shown that in low doses testos-”
BackgroundSelf-citationDynapenia and aging: an update
Manini, T. M., & Clark, B. C. (2012) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glr010 · Cited by 875 · cited 1×
“It was suggested that this should be termed dynapenia [4].”
BackgroundClark, B. C., & Manini, T. M. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.8.829 · Cited by 835 · cited 1×
“clinicians that it was muscle quality, rather than muscle mass that determined the function of muscle [2, 3].”
BackgroundMorley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830 · cited 1×
“Testosterone levels decline at the rate of 1 % per year from 30 years of age [89, 90].”
BackgroundSelf-citationRestoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824 · cited 4×
“Growth differentiation factor (GDF11) Satellite cell rejuvenation 12.”
BackgroundInfluentialPredictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809 · cited 1×
“This decline in testosterone is associated with a decline in muscle mass and strength [91].”
BackgroundSelf-citationAging and vascular endothelial function in humans
Seals, D. R., Jablonski, K. L., & Donato, A. J. (2011) · Clinical Science · doi:10.1042/cs20100476 · Cited by 725 · cited 1×
“With aging, there is a decrease in endothelium-dependent vasodilation, due in part to decreased nitric oxide bioavailability [54].”
BackgroundBeaudart, C., Buckinx, F., Rabenda, V., Gillain, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1742 · Cited by 676 · cited 1×
“Vitamin D supplementation increases muscle strength without increasing muscle mass or power [87].”
BackgroundBauer, J. M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L. M., Maggio, M., McMurdo, M. E. T., Mets, T., Seal, C., Wijers, S. L., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.05.021 · Cited by 670
Nutritional recommendations for the management of sarcopenia
Morley, J. E., Argiles, J. M., Evans, W. J., Bhasin, S., Cella, D., Deutz, N. E. P., Doehner, W., Fearon, K. C. H., Ferrucci, L., Hellerstein, M. K., et al. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.04.014 · Cited by 664 · cited 1×
“There is some evidence for synergistic effects of exercise and protein to enhance muscle function [84–86].”
BackgroundSelf-citationSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundMitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials
Marzetti, E., Calvani, R., Cesari, M., Buford, T. W., Lorenzi, M., Behnke, B. J., & Leeuwenburgh, C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.024 · Cited by 627 · cited 1×
“pathogenesis of aging [47, 48].”
Landi, F., Cruz-Jentoft, A. J., Liperoti, R., Russo, A., Giovannini, S., Tosato, M., Capoluongo, E., Bernabei, R., & Onder, G. (2013) · Age and Ageing · doi:10.1093/ageing/afs194 · Cited by 619 · cited 1×
“This definition was validated as having a strong predictive ability of poor outcomes [6–8].”
BackgroundCohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E., & Goldberg, A. L. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200901052 · Cited by 584 · cited 1×
“Myofibrils constitute the vast majority of muscle protein and their destruction leads to loss of muscle function [57, 58].”
BackgroundPage, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
Tieland, M., Dirks, M. L., van der Zwaluw, N., Verdijk, L. B., van de Rest, O., de Groot, L. C. P. G. M., & van Loon, L. J. C. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.05.020 · Cited by 556
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544 · cited 1×
“terone increased muscle mass and decreases fat mass [95] and in higher doses increased both muscle and power [96].”
BackgroundSatellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly
Verdijk, L. B., Koopman, R., Schaart, G., Meijer, K., Savelberg, H. H. C. M., & van Loon, L. J. C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2006 · Cited by 489
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481 · cited 1×
“In humans with muscular dystrophy, a myostatin antibody (MYO-029) enhanced muscle mass [151].”
BackgroundLeenders, M., Verdijk, L. B., van der Hoeven, L., Adam, J. J., van Kranenburg, J., Nilwik, R., & van Loon, L. J. C. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.02.006 · Cited by 480 · cited 1×
“Persons with diabetes mellitus have accelerated sarcopenia [114–116], and a recent study in diabetics found a decrease in mortality in diabetics receiving testosterone [117].”
BackgroundRolland, Y., Lauwers-Cances, V., Cristini, C., van Kan, G. A., Janssen, I., Morley, J. E., & Vellas, B. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26950 · Cited by 465
Self-citationEffects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study
Morley, J. E., Perry, H. M., Kaiser, F. E., Kraenzle, D., Jensen, J., Houston, K., Mattammal, M., & Perry, H. M. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02049.x · Cited by 463 · cited 1×
“increased muscle strength in older persons [92–94], numerous studies have shown that in low doses testos-”
BackgroundSelf-citationBlackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Tieland, M., van de Rest, O., Dirks, M. L., van der Zwaluw, N., Mensink, M., van Loon, L. J. C., & de Groot, L. C. P. G. M. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.07.005 · Cited by 446 · cited 1×
“2 g (kj day)] may also enhance muscle mass and, to a lesser extent, function [76–80].”
BackgroundCaminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444
Validating the SARC-F: A Suitable Community Screening Tool for Sarcopenia?
Woo, J., Leung, J., & Morley, J. E. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.04.021 · Cited by 422 · cited 1×
“This questionnaire has been shown to be a valid predictor of poor outcomes similar to that of the FNIH (walking speed) definition in both the United States and Asia [13, 16–18].”
ResultSelf-citationMalkin, C. J., Pugh, P. J., West, J. N., van Beek, E. J. R., Jones, T. H., & Channer, K. S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi443 · Cited by 413 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundDalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403 · cited 1×
“In a 12-week study, enobosarm increased total lean mass and stair climb [128].”
BackgroundDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391 · cited 1×
“In female patients with cancer, enobosarm increased lean mass compared to baseline, but not significantly compared to placebo [129].”
BackgroundThe Effect of Vitamin D on Falls: A Systematic Review and Meta-Analysis
Murad, M. H., Elamin, K. B., Abu Elnour, N. O., Elamin, M. B., Alkatib, A. A., Fatourechi, M. M., Almandoz, J. P., Mullan, R. J., Lane, M. A., Liu, H., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1193 · Cited by 390 · cited 1×
“It also decreases falls in persons who are vitamin D deficient [88].”
BackgroundMuraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0321 · Cited by 389
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00005 · Cited by 370 · cited 1×
“Adverse effects include joint and muscle pain, edema, carpal tunnel syndrome, and hyperglycemia [136].”
BackgroundAn evidence-based comparison of operational criteria for the presence of sarcopenia
Dam, T.-T., Peters, K. W., Fragala, M., Cawthon, P. M., Harris, T. B., McLean, R., Shardell, M., Alley, D. E., Kenny, A., Ferrucci, L., et al. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu013 · Cited by 363 · cited 1×
“Subsequently, 4 other definitions of sarcopenia, all using gait speed and grip strength, as well as some measurement of low muscle mass have been published [9–12].”
The role of myostatin in muscle wasting: an overview
Elkina, Y., von Haehling, S., Anker, S. D., & Springer, J. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0035-5 · Cited by 348 · cited 1×
“Myostatin or growth differentiation factor-8 is produced in skeletal muscle and prevents muscle growth and satellite cell production [146].”
BackgroundMotor unit number estimates in the tibialis anterior muscle of young, old, and very old men
McNeil, C. J., Doherty, T. J., Stashuk, D. W., & Rice, C. L. (2005) · Muscle & Nerve · doi:10.1002/mus.20276 · Cited by 345
Wittert, G. A., Chapman, I. M., Haren, M. T., Mackintosh, S., Coates, P., & Morley, J. E. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.7.m618 · Cited by 345 · cited 1×
“terone increased muscle mass and decreases fat mass [95] and in higher doses increased both muscle and power [96].”
BackgroundSelf-citationSarcopenia and Mortality among Older Nursing Home Residents
Landi, F., Liperoti, R., Fusco, D., Mastropaolo, S., Quattrociocchi, D., Proia, A., Tosato, M., Bernabei, R., & Onder, G. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.07.004 · Cited by 344 · cited 1×
“This definition was validated as having a strong predictive ability of poor outcomes [6–8].”
BackgroundInternational working group on Sarcopenia
Chumlea, W. C., Cesari, M., Evans, W. J., Ferrucci, L., Fielding, R. A., Pahor, M., Studenski, S., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0092-7 · Cited by 332
Coen, P. M., Jubrias, S. A., Distefano, G., Amati, F., Mackey, D. C., Glynn, N. W., Manini, T. M., Wohlgemuth, S. E., Leeuwenburgh, C., Cummings, S. R., et al. (2013) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gls196 · Cited by 323 · cited 1×
“The importance of bioenergetics in the development of sarcopenia is demonstrated by the correlation of ATP synthesis/oxygen consumption and walking speed in older persons [49].”
BackgroundLing, C., Poulsen, P., Carlsson, E., Ridderstråle, M., Almgren, P., Wojtaszewski, J., Beck-Nielsen, H., Groop, L., & Vaag, A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21889 · Cited by 300 · cited 1×
“There is a reduction of PGC-1a gene expression in old animals and older persons [45].”
BackgroundCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297 · cited 1×
“A meta-analysis of the controlled studies of testosterone in older males found no increase in mortality [111].”
MethodFrailty, Sarcopenia and Diabetes
Morley, J. E., Malmstrom, T. K., Rodriguez-Mañas, L., & Sinclair, A. J. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.10.001 · Cited by 277
Self-citationSingh, N. A., Quine, S., Clemson, L. M., Williams, E. J., Williamson, D. A., Stavrinos, T. M., Grady, J. N., Perry, T. J., Lloyd, B. D., Smith, E. U. R., et al. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.08.005 · Cited by 274 · cited 1×
“The primary treatment of sarcopenia is resistance exercise [71–73].”
BackgroundLee, W.-J., Liu, L.-K., Peng, L.-N., Lin, M.-H., & Chen, L.-K. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.03.019 · Cited by 266
Defining Sarcopenia in Terms of Incident Adverse Outcomes
Woo, J., Leung, J., & Morley, J. E. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.11.013 · Cited by 261 · cited 1×
“[13] compared each of these definitions and found that they had slightly different predictive abilities.”
ResultSelf-citationFrom cytokine to myokine: The emerging role of interleukin-6 in metabolic regulation
Pal, M., Febbraio, M. A., & Whitham, M. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.16 · Cited by 258 · cited 1×
“Some of these, such as interleukin-6, may be predominantly produced by adipose tissue infiltrating muscle [31].”
BackgroundKenny, A. M., Kleppinger, A., Annis, K., Rathier, M., Browner, B., Judge, J. O., & McGee, D. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02865.x · Cited by 252 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundSumukadas, D., Witham, M. D., Struthers, A. D., & McMurdo, M. E. T. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061339 · Cited by 246 · cited 1×
“It also improved 6-min walking distance in older persons with functional impairment [159].”
BackgroundThe influence of skeletal muscle on systemic aging and lifespan
Demontis, F., Piccirillo, R., Goldberg, A. L., & Perrimon, N. (2013) · Aging Cell · doi:10.1111/acel.12126 · Cited by 238 · cited 1×
“2) [28–30].”
Ferrando, A. A., Paddon-Jones, D., Hays, N. P., Kortebein, P., Ronsen, O., Williams, R. H., McComb, A., Symons, T. B., Wolfe, R. R., & Evans, W. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.03.009 · Cited by 237 · cited 1×
“Essential amino acid supplementation prevents muscle mass loss due to bed rest [82].”
BackgroundMalafarina, V., Uriz-Otano, F., Iniesta, R., & Gil-Guerrero, L. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.08.001 · Cited by 231 · cited 1×
“2 g (kj day)] may also enhance muscle mass and, to a lesser extent, function [76–80].”
BackgroundGarcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Selective androgen receptor modulators as function promoting therapies
Bhasin, S., & Jasuja, R. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a3d79 · Cited by 216 · cited 1×
“More recently, a number of nonsteroidal SARMs have been developed [126].”
BackgroundTestosterone Therapy in Women With Chronic Heart Failure
Iellamo, F., Volterrani, M., Caminiti, G., Karam, R., Massaro, R., Fini, M., Collins, P., & Rosano, G. M. C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.090 · Cited by 215 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundTestosterone Therapy and Cardiovascular Risk: Advances and Controversies
Morgentaler, A., Miner, M. M., Caliber, M., Guay, A. T., Khera, M., & Traish, A. M. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.011 · Cited by 210 · cited 1×
“Whether or not it increases cardiovascular events, and particularly in the first 3 months after administration, remains controversial [112, 113].”
BackgroundTreatment of sporadic inclusion body myositis with bimagrumab
Amato, A. A., Sivakumar, K., Goyal, N., David, W. S., Salajegheh, M., Praestgaard, J., Lach-Trifilieff, E., Trendelenburg, A.-U., Laurent, D., Glass, D. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001070 · Cited by 210 · cited 1×
“In persons with inclusion body myositis, bimagramab increased thigh muscle volume, lean muscle mass, and 6-min walking distance [155].”
BackgroundMohler, M. L., Bohl, C. E., Jones, A., Coss, C. C., Narayanan, R., He, Y., Hwang, D. J., Dalton, J. T., & Miller, D. D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900280m · Cited by 205 · cited 1×
“androgen receptor with differing sensitivity compared to testosterone [125].”
BackgroundCohen, S., Zhai, B., Gygi, S. P., & Goldberg, A. L. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201110067 · Cited by 205 · cited 1×
“Myofibrils constitute the vast majority of muscle protein and their destruction leads to loss of muscle function [57, 58].”
BackgroundKovacheva, E. L., Sinha Hikim, A. P., Shen, R., Sinha, I., & Sinha-Hikim, I. (2010) · Endocrinology · doi:10.1210/en.2009-1177 · Cited by 197 · cited 1×
“In high doses, testosterone activates satellite cell recruitment and reduces adipose stem cells [108].”
BackgroundPapanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0335-x · Cited by 196 · cited 1×
“In females, it increased IGF-1 as well as stair climbing power and gait speed [124].”
BackgroundFRAX® with and without Bone Mineral Density
Kanis, J. A., McCloskey, E., Johansson, H., Oden, A., & Leslie, W. D. (2012) · Calcified Tissue International · doi:10.1007/s00223-011-9544-7 · Cited by 192 · cited 1×
“without Bone Mineral Density are highly predictive of fracture risk [14], we developed a simple sarcopenic questionnaire to predict poor muscle function (Table 2) [15].”
BackgroundSkeletal muscle is an endocrine organ
Iizuka, K., Machida, T., & Hirafuji, M. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14r02cp · Cited by 189
Valenzuela, T. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.11.001 · Cited by 184 · cited 1×
“The primary treatment of sarcopenia is resistance exercise [71–73].”
BackgroundA single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176
Vascular and metabolic response to isolated small muscle mass exercise: effect of age
Lawrenson, L., Poole, J. G., Kim, J., Brown, C., Patel, P., & Richardson, R. S. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00135.2003 · Cited by 176 · cited 1×
“Another component of the development of sarcopenia with aging is the reduction in blood flow to muscles [52, 53].”
BackgroundMitochondrial Involvement and Impact in Aging Skeletal Muscle
Hepple, R. T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00211 · Cited by 175 · cited 1×
“pathogenesis of aging [47, 48].”
Consensus on Cachexia Definitions
Argilés, J. M., Anker, S. D., Evans, W. J., Morley, J. E., Fearon, K. C. H., Strasser, F., Muscaritoli, M., & Baracos, V. E. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.02.004 · Cited by 174
Self-citationFrom sarcopenia to frailty: a road less traveled
Morley, J. E., von Haehling, S., Anker, S. D., & Vellas, B. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0132-3 · Cited by 173 · cited 1×
“Fatigue is an important component of the frailty phenotype that is separate from sarcopenia [33, 34].”
BackgroundSelf-citationEffects of an Oral Growth Hormone Secretagogue in Older Adults
White, H. K., Petrie, C. D., Landschulz, W., MacLean, D., Taylor, A., Lyles, K., Wei, J. Y., Hoffman, A. R., Salvatori, R., Ettinger, M. P., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0632 · Cited by 171 · cited 1×
“Capromorelin, a ghrelin receptor agonist, was tested in older sarcopenic individuals [144].”
BackgroundDifferential effects of aging on limb blood flow in humans
Donato, A. J., Uberoi, A., Wray, D. W., Nishiyama, S., Lawrenson, L., & Richardson, R. S. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00405.2005 · Cited by 169 · cited 1×
“Another component of the development of sarcopenia with aging is the reduction in blood flow to muscles [52, 53].”
BackgroundBasaria, S. S., Collins, L. F., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R. V., Zientek, H., et al. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls078 · Cited by 169
ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling
Seto, J. T., Quinlan, K. G. R., Lek, M., Zheng, X. F., Garton, F., MacArthur, D. G., Hogarth, M. W., Houweling, P. J., Gregorevic, P., Turner, N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67691 · Cited by 164 · cited 1×
“An ACTN3 gene deficiency is associated with reduced power and with endurance activity in men [37, 38].”
BackgroundGhrelin-induced feeding is dependent on nitric oxide
Gaskin, F. S., Farr, S. A., Banks, W. A., Kumar, V. B., & Morley, J. E. (2003) · Peptides · doi:10.1016/s0196-9781(03)00160-8 · Cited by 163 · cited 1×
“These effects of ghrelin are due to the hypothalamic release of nitric oxide [139].”
BackgroundSelf-citationElectrical Stimulation Counteracts Muscle Decline in Seniors
Kern, H., Barberi, L., Löfler, S., Sbardella, S., Burggraf, S., Fruhmann, H., Carraro, U., Mosole, S., Sarabon, N., Vogelauer, M., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00189 · Cited by 161 · cited 1×
“Electrical stimulation of both thighs for 9 weeks improved timed up and go test, walking speed and 5 time chair rise [64].”
MethodTravison, T. G., Basaria, S., Storer, T. W., Jette, A. M., Miciek, R., Farwell, W. R., Choong, K., Lakshman, K., Mazer, N. A., Coviello, A. D., et al. (2011) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr100 · Cited by 160 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundRivas, D. A., Lessard, S. J., Rice, N. P., Lustgarten, M. S., So, K., Goodyear, L. J., Parnell, L. D., & Fielding, R. A. (2014) · The FASEB Journal · doi:10.1096/fj.14-254490 · Cited by 159 · cited 1×
“Decreased skeletal muscle miRNA expression in older persons is associated with a decrease in the function of the IGF-1/PIsK/AKT pathway [61].”
BackgroundDifferential Anabolic Effects of Testosterone and Amino Acid Feeding in Older Men
Ferrando, A. A., Sheffield-Moore, M., Paddon-Jones, D., Wolfe, R. R., & Urban, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021041 · Cited by 156 · cited 1×
“In lower doses, testosterone increases protein synthesis resulting in an increase in muscle mass [106, 107].”
BackgroundThe Effect of Recombinant Human Growth Hormone on Malnourished Older Individuals
Kaiser, F. E., Silver, A. J., & Morley, J. E. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01643.x · Cited by 151 · cited 1×
“Growth hormone, which produces its effects through the release of liver-derived IGF-1, also increased nitrogen retention [135].”
BackgroundSelf-citationMuscle Quantity Is Not Synonymous With Muscle Quality
Barbat‐Artigas, S., Rolland, Y., Vellas, B. J., & Aubertin‐Leheudre, M. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.06.003 · Cited by 149 · cited 1×
“clinicians that it was muscle quality, rather than muscle mass that determined the function of muscle [2, 3].”
BackgroundYamada, M., Arai, H., Sonoda, T., & Aoyama, T. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.04.001 · Cited by 145
Cao, L., Chen, S., Zou, C., Ding, X., Gao, L., Liao, Z., Liu, G., Malmstrom, T. K., Morley, J. E., Flaherty, J. H., et al. (2014) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0410-3 · Cited by 142 · cited 1×
“This questionnaire has been shown to be a valid predictor of poor outcomes similar to that of the FNIH (walking speed) definition in both the United States and Asia [13, 16–18].”
ResultSelf-citationMotoneuron Loss Is Associated With Sarcopenia
Drey, M., Krieger, B., Sieber, C. C., Bauer, J. M., Hettwer, S., Bertsch, T., Dahinden, P., Mäder, A., Vrijbloed, J. W., Schuster, G. M., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.02.002 · Cited by 141
Cohn, L., Feller, A. G., Draper, M. W., Rudman, I. W., & Rudman, D. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02388.x · Cited by 139
Borst, S. E., Shuster, J. J., Zou, B., Ye, F., Jia, H., Wokhlu, A., & Yarrow, J. F. (2014) · BMC Medicine · doi:10.1186/s12916-014-0211-5 · Cited by 135 · cited 1×
“Whether or not it increases cardiovascular events, and particularly in the first 3 months after administration, remains controversial [112, 113].”
Backgroundvan Wetering, C. R., Hoogendoorn, M., Broekhuizen, R., Geraerts-Keeris, G. J. W., Munck, D., Mölken, M. R., & Schols, A. M. W. J. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.12.083 · Cited by 133 · cited 1×
“There is some evidence for synergistic effects of exercise and protein to enhance muscle function [84–86].”
BackgroundHormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132 · cited 1×
“There are marked reductions of circulating IGF-1 with aging [137].”
BackgroundElevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients
Hettwer, S., Dahinden, P., Kucsera, S., Farina, C., Ahmed, S., Fariello, R. G., Drey, M., Sieber, C. C., & Vrijbloed, J. W. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.03.002 · Cited by 122 · cited 1×
“Further evidence of motor neuron degeneration is the increase in C-terminal agrin fragments in about a third of sarcopenic patients [23].”
BackgroundAdaptive processes in skeletal muscle: molecular regulators and genetic influences.
Stewart, C. E., & Rittweger, J. (2006) · PubMed · Cited by 120
Gryson, C., Ratel, S., Rance, M., Penando, S., Bonhomme, C., Ruyet, P. L., Duclos, M., Boirie, Y., & Walrand, S. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.011 · Cited by 118 · cited 1×
“enriched essential amino acids (whey protein) [81].”
Andrés‐Mateos, E., Brinkmeier, H., Burks, T. N., Mejías, R., Files, D. C., Steinberger, M., Soleimani, A. A., Marx, R., Simmers, J. L., Lin, B., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201443 · Cited by 117 · cited 1×
“Serum- and glucocorticoidinducible kinase 1 (SGK1) has been shown to downregulate proteolysis, autophagy and increase protein synthesis in hibernating animals [70].”
BackgroundPurves-Smith, F. M., Sgarioto, N., & Hepple, R. T. (2014) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000012 · Cited by 114 · cited 1×
“Anatomically, with aging there is Type II fiber atrophy resulting in decreased muscle mass, strength, and power [20].”
BackgroundEffects of aging on microvascular oxygen pressures in rat skeletal muscle
Behnke, B. J., Delp, M. D., Dougherty, P. J., Musch, T. I., & Poole, D. C. (2005) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2004.12.009 · Cited by 112 · cited 2×
“decreased microvascular oxygenation of muscles [55].”
BackgroundStout, M., Tew, G. A., Doll, H., Zwierska, I., Woodroofe, M. N., Channer, K. S., & Saxton, J. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.09.016 · Cited by 110 · cited 1×
“In frail older persons [97–99] and in persons with heart failure [100–103] testosterone increased both strength and walking distance.”
BackgroundHutcheon, S., Gillespie, N. D., Crombie, I. K., Struthers, A. D., & McMurdo, M. E. T. (2002) · Heart · doi:10.1136/heart.88.4.373 · Cited by 110 · cited 1×
“Perindopril has been shown to increase distance walked in older persons with left ventricular systolic dysfunction [158].”
BackgroundSarcopenia and Diabetes: Two Sides of the Same Coin
Landi, F., Onder, G., & Bernabei, R. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.004 · Cited by 106 · cited 1×
“Persons with diabetes mellitus have accelerated sarcopenia [114–116], and a recent study in diabetics found a decrease in mortality in diabetics receiving testosterone [117].”
BackgroundChapman, I. M., Visvanathan, R., Hammond, A. J., Morley, J. E., Field, J. B., Tai, K., Belobrajdic, D. P., Chen, R. Y. T., & Horowitz, M. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26538 · Cited by 103 · cited 1×
“decreased hospitalization [105].”
Self-citationGenes and the ageing muscle: a review on genetic association studies
Garatachea, N., & Lucía, A. (2011) · AGE · doi:10.1007/s11357-011-9327-0 · Cited by 102
Haren, M. T., Siddiqui, A. M., Armbrecht, H. J., Kevorkian, R. T., Kim, M. J., Haas, M. J., Mazza, A., Kumar, V. B., Green, M., Banks, W. A., et al. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2010.01061.x · Cited by 99 · cited 1×
“Testosterone effects on muscle cells bypass the WNT system and activate b-catenin [109].”
BackgroundSelf-citationAndrogens and Women at the Menopause and Beyond
Morley, J. E., & Perry, H. M. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.5.m409 · Cited by 98 · cited 1×
“Testosterone improves muscle strength in women as well as in men [104].”
BackgroundSelf-citationA persistent level of Cisd2 extends healthy lifespan and delays aging in mice
Wu, C.-Y., Chen, Y.-F., Wang, C.-H., Kao, C.-H., Zhuang, H.-W., Chen, C.-C., Chen, L.-K., Kirby, R., Wei, Y.-H., Tsai, S.-F., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds210 · Cited by 98 · cited 1×
“Transgenic mice with CisD2 have enhanced longevity and improved muscle quality [51].”
BackgroundRosenberg, I. H., & Roubenoff, R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00014 · Cited by 95 · cited 1×
“Sarcopenia was originally defined as the age-related loss of muscle mass [1].”
BackgroundEffects of oral creatine and resistance training on serum myostatin and GASP-1
Saremi, A., Gharakhanloo, R., Sharghi, S., Gharaati, M. R., Larijani, B., & Omidfar, K. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.12.019 · Cited by 93 · cited 1×
“results in an amplification of the normal decrease in myostatin with resistance training alone [148].”
BackgroundCiliary Neurotrophic Factor is a Regulator of Muscular Strength in Aging
Guillet, C., Auguste, P., Mayo, W., Kreher, P., & Gascan, H. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01257.1999 · Cited by 92 · cited 1×
“Circulating levels of ciliary neurotopic factor (CNTF), which stimulate motor unit formation, decline with aging [25, 26].”
BackgroundConte, M., Vasuri, F., Trisolino, G., Bellavista, E., Santoro, A., Degiovanni, A., Martucci, E., D’Errico, A., Caporossi, D., Capri, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073709 · Cited by 90
Padhi, D., Higano, C. S., Shore, N. D., SIEBER, P. R., Rasmussen, E., & Smith, M. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1271 · Cited by 85 · cited 1×
“Another myostatin antibody (AMG 745) increased lean body mass and decreased fat after 28 days in persons on androgen deprivation therapy for prostate cancer [152].”
BackgroundTargeting myostatin for therapies against muscle-wasting disorders.
Tsuchida, K. (2008) · PubMed · Cited by 84
Peters, R., Beckett, N., Burch, L., de Vernejoul, M.-C., Liu, L., Duggan, J., Swift, C., Gil-Extremera, B., Fletcher, A., & Bulpitt, C. (2010) · Age and Ageing · doi:10.1093/ageing/afq071 · Cited by 84 · cited 1×
“In addition, in the HYVET study perindopril decreased hip fracture [161].”
BackgroundFrisoli, A., Chaves, P. H. M., Pinheiro, M. M., & Szejnfeld, V. L. (2005) · The Journals of Gerontology Series A · doi:10.1093/gerona/60.5.648 · Cited by 84
Physiology of somatostatin receptors.
Guillermet‐Guibert, J., Lahlou, H., Cordelier, P., Bousquet, C., Pyronnet, S., & Susini, C. (2005) · PubMed · Cited by 81
miRNA expression is highly sensitive to a drug therapy in Parkinson's disease
Alieva, A. K., Filatova, E. V., Karabanov, A. V., Illarioshkin, S. N., Limborska, S. A., Shadrina, M. I., & Slominsky, P. A. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.10.018 · Cited by 74 · cited 1×
“There is evidence that miRNAs are sensitive to a variety of drugs such as mu opioids [62] and drugs for Parkinson’s disease [63].”
BackgroundSumukadas, D., Band, M., Miller, S., Cvoro, V., Witham, M., Struthers, A., McConnachie, A., Lloyd, S. M., & McMurdo, M. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt142 · Cited by 73 · cited 1×
“There was, however, no enhancement in persons undergoing exercise training [160].”
BackgroundPötsch, M. S., Tschirner, A., Palus, S., von Haehling, S., Doehner, W., Beadle, J., Coats, A. J. S., Anker, S. D., & Springer, J. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-013-0125-7 · Cited by 72 · cited 1×
“It increases muscle mass and decreases fat mass in older animals [156].”
BackgroundSinha, I., Sinha‐Hikim, A. P., Wagers, A. J., & Sinha‐Hikim, I. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1900-2 · Cited by 68 · cited 1×
“[67] have demonstrated that testosterone plays a permissive role in muscle mass and fiber cross-sectional area in parabiotic mice.”
BackgroundMcGregor, R. A., Poppitt, S., & Cameron‐Smith, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.05.001 · Cited by 67 · cited 1×
“miRNAs play a central role in satellite cell quiescence [60].”
BackgroundAdunsky, A., Chandler, J., Heyden, N., Lutkiewicz, J., Scott, B. B., Berd, Y., Liu, N., & Papanicolaou, D. A. (2011) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2010.10.004 · Cited by 67 · cited 1×
“MK-0677, which also activates the ghrelin receptor to increase growth hormone, was studied for 24 weeks in persons with hip fracture [145].”
BackgroundFajardo, R. J., Manoharan, R. K., Pearsall, R. S., Davies, M. V., Marvell, T. H., Monnell, T. E., Ucran, J. A., Pearsall, A. E., Khanzode, D., Kumar, R., et al. (2009) · Bone · doi:10.1016/j.bone.2009.09.018 · Cited by 66
Coats, A. J. S., Srinivasan, V., Surendran, J., Chiramana, H., Vangipuram, S., Bhatt, N. N., Jain, M. M., Shah, S. A., Ali, I. A. B. H., Ho, G. F., et al. (2011) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0046-2 · Cited by 65 · cited 1×
“A phase II trial showed an increase in muscle mass and a decrease in fat mass [157]: It also increased handrip strength.”
BackgroundPGC-1α and Myokines in the Aging Muscle – A Mini-Review
Arnold, A.-S., Egger, A., & Handschin, C. (2011) · Gerontology · doi:10.1159/000281883 · Cited by 65 · cited 1×
“The peroxisome proliferator-activated receptor c coactivator 1a (PGC-1a) regulates mitochondrial biogenesis and function and regulates muscle fiber adaptation to exercise [44].”
BackgroundWindelinckx, A., Mars, G. D., Huygens, W., Peeters, M., Vincent, B., Wijmenga, C., Lambrechts, D., Delecluse, C., Roth, S. M., Metter, E. J., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.173 · Cited by 61 · cited 1×
“Variants in the activin receptor 1B play an important role in human muscle strength [40].”
BackgroundAnabolic steroids in COPD: a review and preliminary results of a randomized trial
Sharma, S., Arneja, A. S., McLean, L., Duerksen, D. R., Leslie, W. D., Sciberras, D., & Lertzman, M. (2008) · Chronic Respiratory Disease · doi:10.1177/1479972308092350 · Cited by 58 · cited 1×
“increased strength [120–122].”
The effect of α-actinin-3 deficiency on muscle aging
Seto, J. T., Chan, S., Turner, N. A., MacArthur, D. G., Raftery, J. M., Berman, Y. D., Quinlan, K. G. R., Cooney, G. J., Head, S. I., Yang, N., et al. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.006 · Cited by 58
Current topics in testosterone replacement of hypogonadal men
Nieschlag, E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.008 · Cited by 57 · cited 1×
“In view of the fact that testosterone also increases bone mineral density and bone strength [118, 119] and osteoporosis often co-exists with sarcopenia (osteosarcopenia), it would seem that more clinical attention should be paid to the potential role of testosterone for treating sarcopenia.”
BackgroundWang, C., Kao, C.-H., Chen, Y., Wei, Y., & Tsai, T. (2014) · Free Radical Research · doi:10.3109/10715762.2014.936431 · Cited by 56
Sarcopenia--A Critical Perspective
Hepple, R. T. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.46.pe31 · Cited by 54 · cited 1×
“Old muscle shows fiber size heterogeneity and fiber grouping with an increase in myosin heavy chain [21].”
BackgroundCreatine monohydrate in myotonic dystrophy
Walter, M. C., Reilich, P., Lochm�ller, H., Kohnen, R., Schlotter, B., Hautmann, H., Dunkl, E., Pongratz, D., & M�ller-Felber, W. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0923-x · Cited by 53
Macdonald, J. H., Marcora, S., Jibani, M. M., Kumwenda, M. J., Ahmed, W., & LEMMEY, A. B. (2007) · Nephron Clinical Practice · doi:10.1159/000103000 · Cited by 52 · cited 1×
“increased strength [120–122].”
The Motor Unit Number Index (MUNIX) in sarcopenic patients
Drey, M., Grosch, C., Neuwirth, C., Bauer, J. M., & Sieber, C. C. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.01.011 · Cited by 51 · cited 2×
“Sarcopenic patients have a reduction in the motor unit number index (MUNIX) which is intermediate between that seen in healthy older persons and in patients with Amyotropic Lateral Sclerosis [22].”
BackgroundCadore, E. L., & Izquierdo, M. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.04.008 · Cited by 50 · cited 1×
“The primary treatment of sarcopenia is resistance exercise [71–73].”
BackgroundSecretomics for skeletal muscle cells: A discovery of novel regulators?
Yoon, J. H., Kim, J., Song, P., Lee, T. G., Suh, P., & Ryu, S. H. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.03.001 · Cited by 50 · cited 1×
“Proteomics of muscle secretions should lead to the discovery of many more myokines that modulate muscle growth [30].”
BackgroundTestosterone and Muscle Protein Metabolism
Wolfe, R. R., Ferrando, A. A., Sheffield‐Moore, M., & Urban, R. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(19)30644-5 · Cited by 50 · cited 1×
“In lower doses, testosterone increases protein synthesis resulting in an increase in muscle mass [106, 107].”
BackgroundFighting Sarcopenia in Older Frail Subjects: Protein Fuel for Strength, Exercise for Mass
Boirie, Y. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.10.017 · Cited by 48
Variation in the Ciliary Neurotrophic Factor Gene and Muscle Strength in Older Caucasian Women
Arking, D. E., Fallin, M. D., Fried, L. P., Li, T., Beamer, B. A., Xue, Q., Chakravarti, A., & Walston, J. D. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00693.x · Cited by 43 · cited 1×
“Older persons who have the null allele rs1800169 for CNTF have lower grip strength [27].”
BackgroundThe potential of ghrelin in the treatment of cancer cachexia
Argilés, J. M. A., & Stemmler, B. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.727390 · Cited by 40 · cited 1×
“Ghrelin increased food intake and produced muscle mass gain in persons with cancer [140, 141].”
BackgroundHibernation: The search for treatments to prevent disuse-induced skeletal muscle atrophy
Bodine, S. C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.06.003 · Cited by 39 · cited 2×
“MURF-1 and ubiquitin tripartite motif containing”
BackgroundPistilli, E. E., & Quinn, L. S. (2012) · Exercise and Sport Sciences Reviews · doi:10.1097/jes.0b013e318275d230 · Cited by 39 · cited 1×
“IL-15 is an inflammatory cytokine produced by muscle that increases contractile protein accumulation and causes myotube hypertrophy [32].”
BackgroundSullivan, D. H., Carter, W. J., Warr, W., & Williams, L. H. (1998) · The Journals of Gerontology Series A · doi:10.1093/gerona/53a.3.m183 · Cited by 38 · cited 1×
“orthostatic hypotension, gynecomastia, myositis, and edema [138].”
Dennis, R. A., Zhu, H., Kortebein, P. M., Bush, H. M., Harvey, J. F., Sullivan, D. H., & Peterson, C. A. (2009) · Physiological Genomics · doi:10.1152/physiolgenomics.00056.2009 · Cited by 38 · cited 1×
“myostatin correlated most optimally with training-induced strength gains [39].”
BackgroundMicroRNAs: Emerging Role in the Endogenous μ Opioid System
Barbierato, M., Zusso, M., Skaper, S. D., & Giusti, P. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150116123932 · Cited by 33 · cited 1×
“There is evidence that miRNAs are sensitive to a variety of drugs such as mu opioids [62] and drugs for Parkinson’s disease [63].”
BackgroundAntiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?
Fuster, G., Busquets, S., Almendro, V., López-Soriano, F. J., & Argilés, J. M. A. (2007) · Clinical Nutrition · doi:10.1016/j.clnu.2007.07.003 · Cited by 33 · cited 1×
“The extensor digitorum longus muscle of the rat, when incubated with serum obtained from hibernating bears had a 40 % decrease in proteolysis, associated with a decline in cathepsin B and ubiquitin [68].”
BackgroundShould frailty be treated with testosterone?
Morley, J. E. (2010) · The Aging Male · doi:10.3109/13685538.2010.502271 · Cited by 28 · cited 1×
“Testosterone levels decline at the rate of 1 % per year from 30 years of age [89, 90].”
BackgroundSelf-citationGhrelin Level and Body Weight Loss After Esophagectomy for Esophageal Cancer
Miyazaki, T., Tanaka, N., Hirai, H., Yokobori, T., Sano, A., Sakai, M., Inose, T., Sohda, M., Nakajima, M., Fukuchi, M., et al. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.09.016 · Cited by 25 · cited 1×
“Ghrelin increased food intake and produced muscle mass gain in persons with cancer [140, 141].”
BackgroundAnabolic steroids for rehabilitation after hip fracture in older people
Farooqi, V., van den Berg, M., Cameron, I. D., & Crotty, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008887.pub2 · Cited by 24
Scientific overview of hormone treatment used for rejuvenation
Morley, J. E. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.009 · Cited by 24 · cited 1×
“While testosterone as a therapeutic agent has been utilized since the 1940s, there is a fear that it will produce excessive side effects [110].”
BackgroundSelf-citationCermak, N. M., de Groot, C. P. G. M., & van Loon, L. J. C. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.10.003 · Cited by 22 · cited 1×
“2 g (kj day)] may also enhance muscle mass and, to a lesser extent, function [76–80].”
BackgroundBone health in hypogonadal men
Irwig, M. S. (2014) · Current Opinion in Urology · doi:10.1097/mou.0000000000000104 · Cited by 21 · cited 1×
“In view of the fact that testosterone also increases bone mineral density and bone strength [118, 119] and osteoporosis often co-exists with sarcopenia (osteosarcopenia), it would seem that more clinical attention should be paid to the potential role of testosterone for treating sarcopenia.”
BackgroundAbstracts of the 7th Cachexia Conference, Kobe/Osaka, Japan, December 9–11, 2013
Slimani, L., Vazeille, E., Deval, C., Amat, J., Polge, C., Béchet, D., Taillandier, D., Dardevet, D. P., Listrat, A., Attaix, D., et al. (2013) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-013-0123-9 · Cited by 21
Research works printed but not linked: 4
- Rolland Y, Lauwers-Cances V, Crostini C, Abellan van Kan G, Janssen I, Morley JE, Vellas B (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women. EPIDOS Study 89:1895–1900
- Kim MJ, Morley JE (2005) The hormonal fountains of youth: myth or reality? J Endocrinol Invest 28(11):5–14
- Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S et al (2013) Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle 4:334
- Malik F (2013) Fast skeletal muscle troponin activators and their application to disease-preclinical characterization. In: Abstracts, 7th Cachexia Conference, Kobe. p 50
Cited by
International exercise recommendations in older adults (ICFSR): Expert consensus guidelines
Izquierdo, M., Merchant, R. A., Morley, J. E., Anker, S. D., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bernabei, R., Cadore, E. L., Cesari, M., et al. (2021) · The Journal of nutrition, health and aging · doi:10.1007/s12603-021-1665-8 · Cited by 1,247
Self-citationDent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130
Self-citationWelcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Self-citationSarcopenia: A Time for Action. An SCWD Position Paper
Bauer, J., Morley, J. E., Schols, A. M. W. J., Ferrucci, L., Cruz‐Jentoft, A. J., Dent, E., Baracos, V. E., Crawford, J. A., Doehner, W., Heymsfield, S. B., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12483 · Cited by 734
Self-citationSkeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease
Argilés, J. M., Campos, N., Lopez-Pedrosa, J. M., Rueda, R., & Rodriguez-Mañas, L. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.04.019 · Cited by 581
Metadata
- Authors
- Morley, J. E.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Morley, John E.
- ORCID
- Morley, John E.
- Venue
- Calcified Tissue International
- Published
- 2015-06-23
- Volume
- 98
- Issue
- 4
- Pages
- 319-333
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W819537267
- Cited by
- 225
- References
- 161
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 16 · 2023: 15 · 2022: 20 · 2021: 23 · 2020: 20 · 2019: 23 · 2018: 29 · 2017: 27 · 2016: 18 · 2015: 6
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- sarcopenia, sarcopenia treatment, muscle mass loss, muscle function, testosterone replacement therapy, selective androgen receptor modulators, ghrelin agonists, ACE inhibitors, beta-blockers, protein supplementation, vitamin D, resistance training, frailty, older adults
- MeSH terms
- Humans, Drug Discovery, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.